Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia
暂无分享,去创建一个
R. Tubiana | C. Katlama | M. Lê | G. Peytavin | M. Valantin | S. Seang | L. Schneider | L. Assoumou | A. Marcelin | C. Soulié | F. Caby | R. Calin | A. Marcelin | T. Nguyen | Thuy Nguyen | G. Peytavin | Christine Katlama
[1] C. Katlama,et al. Individualized antiretroviral therapeutic approaches: less can be more , 2017, AIDS.
[2] K. Ruxrungtham,et al. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. , 2016, The lancet. HIV.
[3] J. Gallant,et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.
[4] K. Harper. Protease inhibitor monotherapy for long-term management of HIV infection. , 2016, AIDS.
[5] M. Gill,et al. Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients , 2016, PloS one.
[6] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[7] H. Jessen,et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. , 2015, The Lancet. Infectious diseases.
[8] Maria-Silvana Di Yacovo,et al. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. , 2014, The Journal of antimicrobial chemotherapy.
[9] K. Tashima,et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial , 2014, AIDS Research and Therapy.
[10] N. Clumeck,et al. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline , 2012, HIV medicine.
[11] J. Arribas,et al. Analysis of Drug Resistance during HIV RNA Viraemia in the Monet Trial of Darunavir/Ritonavir Monotherapy , 2011, Antiviral therapy.
[12] C. Katlama,et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136 , 2010, AIDS.
[13] M. Boffito,et al. Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients , 2008, HIV clinical trials.
[14] B. Jung,et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.
[15] R. Haubrich,et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients , 2007, AIDS.
[16] C. Katlama,et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 , 2007, AIDS.
[17] M. Egger,et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.